Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and health care issues, announced today that several biotechnology companies are at the forefront of the quest to bring mitogen-activated protein (MAP) kinase pathway-based therapeutics to market, and will do so ahead of most big pharmaceutical companies. According to a new Pathways and Processes report entitled MAP Kinase Pathway Modulators: Emerging Therapeutic Opportunities, MAP kinase- based therapeutics have blockbuster potential in the rheumatoid arthritis, Crohn's disease, ischemic stroke, Parkinson's disease, and prostate cancer drug markets.

"The recent acquisition of Scios by Johnson & Johnson for approximately $2.4 billion underscores the clinical and commercial value of MAP kinase pathway-modulating therapeutics perceived by pharmaceutical companies. This deal also exemplifies the need of pharmaceutical companies to fill their clinical pipelines and to protect their indication-specific franchises," said Sylvia Marecki Ph.D., analyst at Decision Resources. "Biotechs like Scios, Vertex, Celgene, and Cephalon hold strong positions in this field, and partnerships between pharmaceutical companies (including Novartis, Lundbeck, Serono, and Kissei) and biotechs demonstrate that the potential of MAP kinase- based therapeutics to bolster clinical pipelines has not gone unnoticed."

MAP Kinase Pathway -- Facts

The (MAP kinase) signal transduction pathway has tremendous physiological, clinical, and commercial importance because this pathway is critical for cellular responses to external stimuli such as cytokines, stress, and growth factors. Aberrant activation of this pathway is implicated in the pathogenesis of many diseases, which fall into a broad range of therapeutic areas including immune and inflammatory diseases, cardiovascular diseases, central nervous system disorders, and cancer.

Pathways and Processes

MAP Kinase Pathway Modulators: Emerging Therapeutic Opportunities is a report from Pathways and Processes, a new advisory service that focuses on cellular and molecular pathways. The reports provide insight into cutting-edge developments relating to drug targets with the potential to significantly change treatment practice and impact multiple pharmaceutical markets.

About Decision Resources

Decision Resources, Inc. is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at www.decisionresources.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   For more information, contact:    Elizabeth Marshall    Decision Resources    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, +1-781-296-2563,
emarshall@dresources.com

Dramatic Expansion Predicted for the Rheumatoid Arthritis Drug Market

View Now